All High-Throughput Screening (HTS) articles – Page 9
-
NewsAssociations of AML MRD levels with posttransplant clinical outcomes
Patients with no detectable FLT3 mutations had the best outcomes after an allogenic hematopoietic cell transplant.
-
WhitepaperPoster: Assays for PRMT5, MLL4, METTL3/14, & NSP14
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
-
NewsQuantitative assessment of cerebral small vessel disease risk
Researchers discovered that measuring the concentrations of IL-18 in an individual’s blood could estimate future risk of stroke.
-
NewsNew methodologies to find microbiome biomarkers
Confounder control and quantitative profiling revealed misleading associations between microbial markers and colorectal cancer development.
-
NewsNew screening method for HPV-positive head and neck cancer
A urine-based test that detects ctDNA from HPV-positive head and neck cancers could facilitate its early detection.
-
WebinarSAFIRE: AI predicted ADME for drug discovery: leveraging BioPrint
Join Dr Carleton Sage to learn about predicting ADME properties as a key approach to improving the efficiency of small molecule drug discovery. AI ADME model development approaches and case studies within drug discovery projects will be discussed.
-
NewsHereditary Alzheimer’s disease can be transferred via transplants
Transplant recipients of hematopoietic stem cells with a hereditary version of AD developed the disease at an accelerated rate.
-
NewsFGF2 and SOX17 enable more efficient stem cell differentiation
The discovery of two proteins that effectively mature hiPSCs into endothelial cells may have a range of research and clinical benefits.
-
NewsExact bacterial lineage associated with colorectal cancer pinpointed
Researchers have discovered two distinct lineages of Fusobacterium nucleatum, which has great implications for colorectal cancer screening and therapeutics.
-
ArticleCRISPR/Cas: exploring its impact on gene editing
Tune in to this episode where we discuss the opportunities CRISPR/Cas technology offers to revolutionise drug discovery.
-
NewsNovel tool to rapidly diagnose sarcoidosis
A highly specific blood test can differentiate between patients with sarcoidosis and other respiratory conditions, like TB or lung cancer.
-
ArticleHigh-throughput screening: rapid advancements in drug discovery
Listen to this podcast where we explore the latest technological advancements in high throughput screening and more.
-
WebinarIon Channel Drug Discovery - Recent Advances in Novel Non-Opioid Pain Research
Watch this webinar to learn about recently published research toward the advancement of non-opioid analgesics targeting the Nav1.8 ion channel, a validated pain target primarily found in peripheral nociceptors.
-
VideoVideo: Dianthus for identifying Microcycle® hits
Hear how Dr. Reece Gardner from Curve Therapeutics uses the Dianthus instrument with Spectral Shift technology to validate Microcycle® hits.
-
NewsSPOCD1 and C19ORF84: insights into severe male infertility
Researchers have discovered the role of two genes that protect mammalian germ cells, which could influence male fertility.
-
NewsNew molecular imaging technique improves breast cancer diagnostics
Low-dose positron emission mammography (PEM) has a high sensitivity for detecting cancer and reduces the likelihood of false positives.
-
NewsMulti-omic approach classifies biomarkers for paediatric sepsis
Researchers have discovered potential biomarkers to identify paediatric sepsis progression stage, enabling more targeted treatment.
-
ArticleeBook: Reveal Cell Function With Single-Cell Resolution
This eBook explores a new means to perform single-cell functional analysis. Uncover the Xdrop®single-cell format workflow with its ability to help identify, quantify, and comprehend immune cell functions at the individual cellular level.
-
WhitepaperA Guide to Measuring Drug-Target Residence Times
This guide provides technical background on concepts and techniques for use of Transcreener biochemical assays to measure drug-target residence times.
-
WhitepaperMEA to probe ALS phenotypes in neuronal disease models
Explore an MEA workflow used to validate the ALS-relevant phenotype of precision reprogrammed iPSC-derived neuronal disease models of ALS from bit.bio